

Notice of Allowability

Application No.

10/029,750

Examiner

Robert Shiao

Applicant(s)

LIN ET AL.

Art Unit

1626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 08/18, 2004.
2. ☒ The allowed claim(s) is/are 48-59, now are 1-12.
3. ☐ The drawings filed on _____ are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
 6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No./Mail Date _____
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☒ Interview Summary (PTO-413), Paper No./Mail Date _____
7. ☒ Examiner's Amendment/Comment
8. ☒ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____

DETAILED ACTION

1. This application claims benefit of the provisional application: 60/257,703 with a filing date 12/22, 2000.
2. Applicant's amendment including cancellation of claims 1-47, and addition of claims 48-74 in the amendment filed on August 18, 2004, is acknowledged. No new matter is found. Claims 48-74 are pending in the application. Since the newly added claims 48-74 are commensurate with the scope of the invention, therefore, claims 48-74 are prosecuted in the case.

Responses to Amendment

3. Since the variable R₃ of the compounds of the formula in claim 48 still represents amino independently substituted with hydrogen, alkyl, or aryl, therefore, rejection of claims 48-74 (i.e., previously 1-23, and 36-44) under 35 U.S.C. 103(a) is maintained.

EXAMINER'S AMENDMENT

4. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Hesna J. Pfelffer on November 2, 2004. The application has been amended as follows:

Art Unit: 1626

In claim 48, page 3, line 20, after "-CO₂(C₁₋₈)alkyl, delete "amino"

In claim 48, page 3, line 22, after "consisting of hydrogen", delete "and C₁₋₈alkyl"

In claim 48, page 4, line 26, after "imidazoliny, and triazolyl", insert

--, with a proviso when R₃ is amino substituted with two substitutents, the two substitutents independently are not selected from hydrogen and aryl, wherein aryl is phenyl--

In claim 51, page 9, line 8, delete "C(O) 1,2,3-thiadiazol-4-yl 4-SO₂-NH₂;"

In claim 51, page 9, line 25, delete "C(O) Ph(C)₂ 4-SO₂-NH₂;"

Delete claims **60-74**

Reasons for Allowance

5. The following is an examiner's statement of reasons for allowance:

Claims 48-59 are neither anticipated nor rendered obvious over the art of record, and therefore are allowable. This invention relates to substituted triazole diamine derivatives as kinase inhibitors. The closest prior art is Akahoshi et al. 5,750,545, disclose triazole derivatives and pharmaceutical use thereof. The difference between prior art and instant claims is that the variable R₃ of instant compounds of the formula of claim 48 is not amino, and when R₃ is amino substituted with two substitutents, the two substitutents independently are not selected from hydrogen, alkyl, and aryl, wherein

aryl is phenyl. Suggestion for modification of reference to obtain the instant compounds/compositions has not been found. Claims 48-59 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Shiao whose telephone number is (571) 272-0707. The examiner can normally be reached on 8:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. McKane can be reached on (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

A handwritten signature in black ink, appearing to read "Rita Desai", with a long horizontal line extending from the end of the signature.

Rita Desai
Primary Patent Examiner
Technology Center 1600
Tel: (571) 272-0684

A handwritten signature in black ink, appearing to read "R. Shiao", with a horizontal line extending from the end of the signature.

Robert Shiao, Ph.D.
Patent Examiner
Art Unit 1626

11/1/04

November 2, 2004